129 related articles for article (PubMed ID: 19075480)
1. Long-term coronary endothelial function after zotarolimus-eluting stent implantation. A 9 month comparison between zotarolimus-eluting and sirolimus-eluting stents.
Shin DI; Seung KB; Kim PJ; Chang K; Choi JK; Jeon DS; Kim MJ; Lee MY; Chung WS
Int Heart J; 2008 Nov; 49(6):639-52. PubMed ID: 19075480
[TBL] [Abstract][Full Text] [Related]
2. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction.
Kim JW; Seo HS; Park JH; Na JO; Choi CU; Lim HE; Kim EJ; Rha SW; Park CG; Oh DJ
J Am Coll Cardiol; 2009 May; 53(18):1653-9. PubMed ID: 19406340
[TBL] [Abstract][Full Text] [Related]
3. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction.
Shin DI; Kim PJ; Seung KB; Kim DB; Kim MJ; Chang K; Lim SM; Jeon DS; Chung WS; Baek SH; Lee MY
Int Heart J; 2007 Sep; 48(5):553-67. PubMed ID: 17998765
[TBL] [Abstract][Full Text] [Related]
4. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses.
Hamilos M; Sarma J; Ostojic M; Cuisset T; Sarno G; Melikian N; Ntalianis A; Muller O; Barbato E; Beleslin B; Sagic D; De Bruyne B; Bartunek J; Wijns W
Circ Cardiovasc Interv; 2008 Dec; 1(3):193-200. PubMed ID: 20031678
[TBL] [Abstract][Full Text] [Related]
5. Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study.
Rusinaru D; Vrolix M; Verheye S; Chowdhary S; Schoors D; Di Mario C; Desmet W; Donohoe DJ; Ormiston JA; Knape C; Bezerra H; Lansky A; Wijns W;
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1141-50. PubMed ID: 25044635
[TBL] [Abstract][Full Text] [Related]
6. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus Paclitaxel-eluting stent.
Kim JW; Suh SY; Choi CU; Na JO; Kim EJ; Rha SW; Park CG; Seo HS; Oh DJ
JACC Cardiovasc Interv; 2008 Feb; 1(1):65-71. PubMed ID: 19393147
[TBL] [Abstract][Full Text] [Related]
7. Morphological, Functional, and Biological Vascular Healing Response 6 Months After Drug-Eluting Stent Implantation: A Randomized Comparison of Three Drug-Eluting Stents.
Nakata T; Fujii K; Fukunaga M; Shibuya M; Kawai K; Kawasaki D; Naito Y; Ohyanagi M; Masuyama T
Catheter Cardiovasc Interv; 2016 Sep; 88(3):350-7. PubMed ID: 26526816
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.
Hamilos MI; Ostojic M; Beleslin B; Sagic D; Mangovski L; Stojkovic S; Nedeljkovic M; Orlic D; Milosavljevic B; Topic D; Karanovic N; Wijns W;
J Am Coll Cardiol; 2008 Jun; 51(22):2123-9. PubMed ID: 18510958
[TBL] [Abstract][Full Text] [Related]
9. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
10. Comparison of zotarolimus-eluting stents with sirolimus-eluting and paclitaxel-eluting stents: intimal hyperplasia and vascular changes assessed by volumetric intravascular ultrasound analysis.
Kang SJ; Mintz GS; Park DW; Lee SW; Kim YH; Lee CW; Han KH; Kim JJ; Park SW; Park SJ
Circ Cardiovasc Interv; 2011 Apr; 4(2):139-45. PubMed ID: 21364151
[TBL] [Abstract][Full Text] [Related]
11. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 3-year clinical outcomes between Resolute™ zotarolimus- and sirolimus-eluting stents for long coronary artery stenosis.
Im E; Kim BK; Ko YG; Her AY; Choi HH; Shin DH; Kim JS; Choi D; Jang Y; Hong MK
J Interv Cardiol; 2013 Aug; 26(4):378-83. PubMed ID: 23844852
[TBL] [Abstract][Full Text] [Related]
13. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of sirolimus-eluting stent versus bare metal stent evaluation of the coronary endothelial dysfunction in the same patient presenting with multiple coronary artery lesions: the CREDENTIAL study.
Mischie AN; Nazzaro MS; Fiorilli R; De Felice F; Musto C; Confessore P; Parma A; Boschetti C; Violini R
Catheter Cardiovasc Interv; 2013 Sep; 82(3):E184-91. PubMed ID: 23359371
[TBL] [Abstract][Full Text] [Related]
15. Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
Sethi A; Bahekar A; Bhuriya R; Bajaj A; Singh PP; Arora R; Khosla S
Arch Cardiovasc Dis; 2012 Nov; 105(11):544-56. PubMed ID: 23177483
[TBL] [Abstract][Full Text] [Related]
16. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents.
Nakazawa G; Finn AV; John MC; Kolodgie FD; Virmani R
Am J Cardiol; 2007 Oct; 100(8B):36M-44M. PubMed ID: 17950831
[TBL] [Abstract][Full Text] [Related]
17. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
[TBL] [Abstract][Full Text] [Related]
18. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation.
Fuke S; Maekawa K; Kawamoto K; Saito H; Sato T; Hioka T; Ohe T
Circ J; 2007 Feb; 71(2):220-5. PubMed ID: 17251671
[TBL] [Abstract][Full Text] [Related]
19. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction.
Togni M; Windecker S; Cocchia R; Wenaweser P; Cook S; Billinger M; Meier B; Hess OM
J Am Coll Cardiol; 2005 Jul; 46(2):231-6. PubMed ID: 16022947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
